Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Histopathology. 2022 Mar;80(4):677-685. doi: 10.1111/his.14599. Epub 2022 Jan 5.
Large cell calcifying Sertoli cell tumour (LCCSCT) is a rare testicular sex cord-stromal tumour that primarily affects young patients and is associated with Carney complex. We sought to characterise the clinicopathological features of a series of LCCSCT and evaluate the diagnostic utility of PRKAR1A immunohistochemistry (IHC).
The LCCSCT cohort (n = 15) had a median age of 16 years (range = 2-30 years). Four patients were known to have Carney complex. PRKAR1A IHC was performed in each case. For comparison, PRKAR1A IHC was also assessed in other sex cord-stromal tumours, including Sertoli cell tumour, not otherwise specified (SCT, NOS; n = 10), intratubular large cell hyalinising Sertoli cell tumour (n = 1) and Leydig cell tumour (n = 23). Loss of cytoplasmic PRKAR1A expression was observed in all but one LCCSCT (14 of 15; 93%). PRKAR1A expression was retained in all SCTs, NOS (10 of 10; 100%), the majority of Leydig cell tumours (22 of 23; 96%) and an intratubular large cell hyalinising Sertoli cell tumour (1 of 1; 100%). One Leydig cell tumour showed equivocal staining (multifocal weak expression).
Overall, PRKAR1A loss is both sensitive (93%) and highly specific (97%) for the diagnosis of LCCSCT. PRKAR1A loss may aid its diagnosis, particularly in sporadic cases and those that are the first presentation of Carney complex.
大细胞钙化性支持细胞瘤(LCCSCT)是一种罕见的睾丸性索-间质肿瘤,主要影响年轻患者,与卡尼综合征有关。我们旨在描述一系列 LCCSCT 的临床病理特征,并评估 PRKAR1A 免疫组织化学(IHC)的诊断效用。
LCCSCT 队列(n=15)的中位年龄为 16 岁(范围=2-30 岁)。有 4 名患者已知患有卡尼综合征。对每个病例均进行 PRKAR1A IHC。为了比较,还评估了 PRKAR1A IHC 在其他性索-间质肿瘤中的表达,包括未特指的 Sertoli 细胞瘤(SCT,NOS;n=10)、小管内大细胞透明化 Sertoli 细胞瘤(n=1)和 Leydig 细胞瘤(n=23)。除 1 例外,所有 LCCSCT(14/15;93%)均观察到细胞质 PRKAR1A 表达缺失。所有 SCT、NOS(10/10;100%)、大多数 Leydig 细胞瘤(22/23;96%)和 1 例小管内大细胞透明化 Sertoli 细胞瘤(1/1;100%)均保留了 PRKAR1A 表达。1 例 Leydig 细胞瘤表现为不确定染色(多灶性弱表达)。
总体而言,PRKAR1A 缺失对 LCCSCT 的诊断具有高度敏感性(93%)和特异性(97%)。PRKAR1A 缺失可能有助于其诊断,特别是在散发性病例和卡尼综合征的首发表现中。